Table 3 Impact of baseline characteristics on PFS in univariate and multivariate analysis
From: Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients
Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
HR(95%CI) | P value | HR(95%CI) | P value | |
CD27- vs. CD27+ | 0.510 (0.307–0.848) | 0.009** | 0.496 (0.294–0.838) | 0.009** |
CD117- vs. CD117+ | 0.717 (0.443–1.162) | 0.177 | ||
ISS stage III vs. I + II | 1.253 (0.792–1.981) | 0.335 | ||
DS stage III vs. I + II | 2.230 (1.106–4.493) | 0.025* | 1.781 (0.841–3.769) | 0.132 |
MASS stage III vs. I + II | 0.996 (0.609–1.533) | 0.884 | ||
Age ≥ 65 vs. <65 | 0.799 (0.474–1.349) | 0.402 | ||
Sex (male vs. female) | 0.744 (0.467–1.187) | 0.215 | ||
Prior ASCT | 0.925 (0.572–1.496) | 0.750 | ||
PI-based programmes | 0.674 (0.409–1.109) | 0.120 | ||
IMiD-based programmes | 1.111 (0.267–4.620) | 0.885 | ||
Mb Combination Programmes | 1.503 (0.901–2.507) | 0.119 | ||
PLT ≥ 150 vs. <150 × 109/L | 2.354 (1.474–3.759) | <0.0001*** | 2.278 (1.358–3.820) | 0.002** |
Hb ≥ 100 vs. <100 g/L | 1.760 (1.101–2.811) | 0.018* | 1.236 (0.733–2.085) | 0.426 |
Albumin ≥ 35 vs. <35 g/L | 1.061 (0.651–1.729) | 0.812 | ||
LDH ≥ 222 vs. <222U/L | 1.172 (0.643–2.137) | 0.604 | ||
Creatinine (Cre) ≥ 111 vs. <111umol/L | 1.516 (0.923–2.492) | 0.100 | ||
ALP ≥ 135 vs. <135U/L | 1.008 (0.435–2.338) | 0.985 | ||
CK ≥ 180 vs. <180U/L | 0.488 (0.150–1.589) | 0.233 | ||
Ca ≥ 2.5 vs. <2.5mmol/L | 1.179 (0.475–2.928) | 0.723 | ||
URIC ≥ 400 vs. <400umol/L | 1.001 (0.627–1.596) | 0.998 | ||
UREA ≥ 7 vs. <7mmol/L | 0.971 (0.593–1.590) | 0.907 | ||
β2-MG < 5.5 vs. ≥5.5 mg/L | 1.602 (1.002–2.563) | 0.049* | 0.840 (0.485–1.454) | 0.534 |